New York R&D Center For Translational Medicine And Therapeutics, Inc.

New York R&D Center For Translational Medicine And Therapeutics, Inc. is a for-profit corporate entity registered in SAM.gov since June 2013, located in New Rochelle, New York. The organization specializes in medical research and development, focusing on innovative therapeutic approaches for medical conditions, particularly in the areas of tendon disorders and regenerative medicine. As a research-focused organization, the company appears to be dedicated to developing novel medical treatments and biologics that address unmet medical needs, with a specific emphasis on translational medicine that bridges laboratory research to potential clinical applications.

The organization has received multiple federal grant awards from agencies including the National Institute on Aging and the Defense Health Agency, concentrating on advanced therapeutic research for tendinopathy and tendon-related medical interventions. Their grant-funded projects include developing innovative treatments such as a microRNA-based strategy for tendon repair (Award ID: W81XWH2210412), an exosome drug for tendinopathy utilizing mesenchymal stem cells (Award ID: R44AG084503), and a microRNA (miR-221-5p) treatment for tendon disorders (Award ID: R44AG081162). These projects demonstrate a sophisticated approach to medical research, involving complex biological interventions like chemically modified microRNAs, exosome-based therapies, and preclinical studies in animal models to evaluate efficacy and safety. The research aims to develop potential FDA-approved treatments for age-related tendon disorders, with a particular focus on mitigating pain, improving mechanical properties, and addressing inflammatory processes associated with tendon deterioration.